AbCellera Biologics Inc. · Q3 2023
ReportedNov 2, 2023
Period endedSep 30, 2023
The quarter in short
Revenue $7M, down 34.4% on the quarter. EPS −$0.10, up 9.1% on the quarter. Free cash flow −$20M, down 180.0% on the quarter.
Reported this quarter
Revenue
$7M
QoQ −34.4%
YoY —
EPS
−$0.10
QoQ +9.1%
YoY —
Free Cash Flow
−$20M
QoQ −180.0%
YoY —
FCF Margin
-309.7%
QoQ −237.1 pp
YoY —
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1703057.
HTML
8-K results announcement
Filed Nov 2, 2023
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
18 KB
HTM
Exhibit EX-99.2
Exhibit 99.2 to the 8-K
15 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Sep 30, 2023, filed Nov 2, 2023
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure ABCL has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q3 2023, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings